Boosting effect of high-dose influenza vaccination on innate immunity among elderly
Authors:
- Olivia BonduelleOBOlivia Bonduelle
- Tristan DeloryTDTristan Delory
- Marion GhidiMGMarion Ghidi
- Selma BennacerSBSelma Bennacer
- Michele WokamMWMichele Wokam
- Mathieu LenormandMLMathieu Lenormand
- Melissa PetrierMPMelissa Petrier
- Olivier RogeauxOROlivier Rogeaux
- Simon de BernardSBSimon de Bernard
- Karine AlvesKAKarine Alves
- Julien NourikyanJNJulien Nourikyan
Open Access
- 4 March 2025
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (8)
Abstract
BACKGROUND: The high-dose quadrivalent influenza vaccine (QIV-HD) showed superior efficacy against laboratory-confirmed illness compared with the standard-dose quadrivalent influenza vaccine (QIV-SD) in randomized controlled trials with the elderly. However, specific underlying mechanism remains unclear. METHODS: This phase IV randomized controlled trial compared early innate responses induced by QIV-HD and QIV-SD in 59 individuals aged > 65 years. Systemic innate cells and gene signatures at day 0 (D0) and D1 as well as hemagglutinin inhibition antibody (HIA) titers at D0 and D21 after vaccination were assessed. RESULTS: QIV-HD elicited robust humoral response with significantly higher antibody titers and seroconversion rates than QIV-SD. At D1 after vaccination, QIV-HD recipients showed significant reduction in innate cells, including conventional DCs and NK cells, compared with QIV-SD, correlating with significantly increased HIA titers at D21. Blood transcriptomic analysis revealed greater amplitude of gene expression in the QIV-HD arm, encompassing genes related to innate immune response, IFNs, and antigen processing and presentation, and correlated with humoral responses. Interestingly, comparative analysis with a literature dataset from young adults vaccinated with influenza standard-dose vaccine highlighted strong similarities in gene expression patterns and biological pathways with the elderly vaccinated with QIV-HD. CONCLUSION: QIV-HD induces higher HIA titers than QIV-SD, a youthful boost of the innate gene expression significantly associated with high HIA titers. TRIAL REGISTRATION: EudraCT no. 2021-004573-32.Keywords
Funding Information
- Sanofi Pasteur S.A. (E003603032)
This publication has 34 references indexed in Scilit:
- Systems biology of vaccination for seasonal influenza in humansNature Immunology, 2011
- Immunological mechanisms of vaccinationNature Immunology, 2011
- Systems Biology in Immunology: A Computational Modeling PerspectiveAnnual Review of Immunology, 2011
- Early Patterns of Gene Expression Correlate With the Humoral Immune Response to Influenza Vaccination in HumansThe Journal of Infectious Diseases, 2011
- Programming the magnitude and persistence of antibody responses with innate immunityNature, 2011
- Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and OlderThe Journal of Infectious Diseases, 2009
- Differential Antigen Processing by Dendritic Cell Subsets in VivoScience, 2007
- Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subsetBlood, 2001
- Differential Expression and Function of L-Selectin on CD56bright and CD56dim Natural Killer Cell SubsetsThe Journal of Immunology, 1998
- Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.Journal of Experimental Medicine, 1992